|
End-of-day quote
Other stock markets
|
||
| - USD | - |
|
| 06-18 | FDA Seeks Updated Labeling for Testosterone Therapies | MT |
| 06-09 | Wall Street Rises, Risks Remain |
| Market Cap | 1.42B 1.24B 1.15B 1.07B 2.01B 134B 2.02B 13.59B 5.27B 65.87B 5.32B 5.21B 229B | P/E 2026 * |
-73.2x | P/E 2027 * | 8.84x |
|---|---|---|---|---|---|
| Enterprise Value | 4.36B 3.8B 3.52B 3.29B 6.18B 411B 6.21B 41.74B 16.18B 202B 16.36B 16.01B 703B | EV / Sales 2026 * |
1.07x | EV / Sales 2027 * | 1.04x |
| Free-Float |
99.61% | Yield 2026 * |
11.3% | Yield 2027 * | 11.5% |
Last Transcript: PERRIGO
| Manager | Title | Age | Since |
|---|---|---|---|
Albert Manzone
CEO | Chief Executive Officer | 63 | 2026-06-06 |
Eduardo Bezerra
DFI | Director of Finance/CFO | 51 | 2022-05-15 |
Matt Winterman
COO | Chief Operating Officer | - | 2025-06-22 |
| Director | Title | Age | Since |
|---|---|---|---|
Donal O'Connor
BRD | Director/Board Member | 75 | 2014-10-31 |
Geoffrey Parker
BRD | Director/Board Member | 61 | 2016-11-06 |
Bradley Alford
BRD | Director/Board Member | 70 | 2017-02-05 |
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
| -1.21% | -3.04% | +44.03% | +143.07% | 980B | ||
| -2.48% | -5.18% | +52.47% | +39.15% | 550B | ||
| -2.14% | -4.94% | +16.83% | +57.08% | 382B | ||
| +0.25% | -3.09% | +23.33% | +16.04% | 316B | ||
| +0.61% | -1.69% | +27.35% | +13.73% | 272B | ||
| +0.22% | -3.10% | +24.67% | +30.49% | 268B | ||
| +4.59% | +1.98% | -38.43% | -46.26% | 199B | ||
| -1.19% | -4.95% | +16.68% | +47.69% | 182B | ||
| -1.35% | -1.46% | +14.06% | +59.26% | 154B | ||
| Average | -0.30% | -3.02% | +20.11% | +40.03% | 366.93B | |
| Weighted average by Cap. | -0.78% | -3.68% | +29.49% | +63.31% |
| 2026 * | 2027 * | |
|---|---|---|
| Net sales | 4.06B 3.54B 3.28B 3.07B 5.75B 383B 5.79B 38.86B 15.06B 188B 15.23B 14.9B 654B | 4.1B 3.57B 3.31B 3.1B 5.81B 387B 5.85B 39.26B 15.22B 190B 15.38B 15.05B 661B |
| Net income | -339M -296M -274M -256M -481M -31.99B -484M -3.25B -1.26B -15.74B -1.27B -1.25B -54.67B | 161M 141M 130M 122M 229M 15.23B 230M 1.55B 599M 7.5B 606M 593M 26.03B |
| Net Debt | 2.94B 2.56B 2.37B 2.22B 4.17B 277B 4.19B 28.15B 10.91B 136B 11.03B 10.8B 474B | 2.83B 2.47B 2.28B 2.14B 4.01B 267B 4.03B 27.09B 10.5B 131B 10.62B 10.39B 456B |
Trader
This super rating is the result of a weighted average of the rankings based on the following ratings: Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite) and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be carried out. We recommend that you carefully review the associated descriptions.
Quality
This composite rating is the result of an average of rankings based on the following ratings: Returns (Composite), Profitability (Composite) and Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully read the associated descriptions.
ESG MSCI
The MSCI ESG score assesses a company’s environmental, social, and governance practices relative to its industry peers. Companies are rated from CCC (laggard) to AAA (leader). This rating helps investors incorporate sustainability risks and opportunities into their investment decisions.
Select your edition
All financial news and data tailored to specific country editions

















